American Regent, Inc., a U.S. manufacturer of pharmaceuticals for human and veterinary use with manufacturing sites in New York and Ohio, has acquired HBT Labs, Inc. based in California. HBT Labs has a pipeline of generic and 505(b)(2) pharmaceutical products that target various treatment indications including cancer and central nervous system (CNS) disorders. “Our acquisition of HBT Labs supports our growing product portfolio, efforts to expand into the oncology market, and dedication ...